Seeking Alpha

stock-PR.com's  Instablog

stock-PR.com
Send Message
View stock-PR.com's Instablogs on:
  • Positive Data Results: Coronado Biosciences (BNDO), AcelRx Pharmaceuticals (ACRX)

    http://static.cdn-seekingalpha.com/uploads/2013/10/28/saupload_mike_zaman_logo.jpg

    http://static.cdn-seekingalpha.com/uploads/2012/9/5/saupload_cndo.jpg Coronado Biosciences, Inc. (NASDAQ:CNDO)

    Autism spectrum disorder and autism are both general terms for a group of complex disorders of brain development. These disorders are characterized by three core symptoms: difficulties in social interaction, verbal and nonverbal communication and repetitive behaviors.

    Autism can be associated with intellectual disability, difficulties in motor coordination and attention and physical health issues such as sleep and gastrointestinal disturbances. Some persons with Autism excel in visual skills, music, math and art.

    Autism statistics from the U.S. Centers for Disease Control and Prevention identify around 1 in 88 American children as on the autism spectrum–a ten-fold increase in prevalence in 40 years

    Autism Speaks, the world’s leading autism science and advocacy organization, reported in March 2012 preliminary results of new research that estimates autism costs society $126B per year in the US – a number that has more than tripled since 2006.

    CNDO reported a presentation of interim data from a pilot study of oral TSO (Trichuris suis ova or CNDO-201) to treat autism.

    The study is a double-blind, randomized, placebo-controlled, cross-over study and enrolled 10 high-functioning adult autism spectrum disorder patients who were able to give informed consent to participate in the study and who had a history of allergies and/or a family history of immune-inflammatory illness. They were treated for 12 weeks with either TSO or placebo, followed by a 4-week washout phase and then 12 weeks of placebo or TSO. The TSO dosage used in the study was 2,500 ova once every two weeks.

    The treatment was well tolerated. The study is still ongoing and final results are expected in the middle of 2014.

    CNDO believes autism is an area of unmet medical need where a natural immune system regulator like TSO (Trichuris suis ova or CNDO-201) may help a part of the autism population

    http://static.cdn-seekingalpha.com/uploads/2013/12/13/saupload_cndo_chart.png

    CNDO is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer.

    More about Coronado Biosciences, Inc. (CNDO) at www.coronadobiosciences.com

    **

    http://static.cdn-seekingalpha.com/uploads/2013/10/16/saupload_crwe_logo.jpg Crown Equity Holdings Inc. (OTCPK:CRWE)

    CRWE is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, is targeting the multi-billion dollar social networking service market.

    A social networking service is an online service, platform, or site that focuses on facilitating the building of social networks or social relations among people who, for example, share interests, activities, backgrounds, or real-life connections.

    CRWE is currently developing a social networking service and phone app, CRWE Network (CRWE-PR), that is designed to target all the communities in every state of the United States.

    CRWE‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

    http://static.cdn-seekingalpha.com/uploads/2013/12/13/saupload_crwedec13.png

    CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.

    More about Crown Equity Holdings Inc. (OTCPK:CRWE) at www.crownequityholdings.com.

    **

    http://static.cdn-seekingalpha.com/uploads/2013/12/13/saupload_acrx.jpg AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

    ACRX presented additional detail from the Phase 2 dose-finding study of its ARX-04, an investigational single-dose sublingual sufentanil NanoTab for moderate-to-severe acute pain, for which topline results were reported in April 2013.

    Patients treated with the 30 mcg dose of sufentanil showed a rapid onset of action with a statistically significant beneficial difference in pain relief and pain intensity seen at 30 minutes after dosing compared to placebo.

    ARX-04 is a product candidate in development for the treatment of moderate-to-severe acute pain, consisting of sufentanil, a high therapeutic index opioid, formulated using ACRX's proprietary NanoTab technology that enables rapid sublingual absorption when the NanoTab is placed under the tongue.

    http://static.cdn-seekingalpha.com/uploads/2013/12/13/saupload_acrx_chart1.png

    ACRX is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.

    More about AcelRx Pharmaceuticals, Inc. (ACRX) at www.acelrx.com.

    **

    Read Full Disclaimer at www.mikezaman.com/disclaimer

    mikezaman.com/27244/stocks/positive-data.../

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Dec 13 10:09 AM | Link | Comment!
  • VIVUS (VVUS) Agreement With Sanofi For Avanafil, Canadian Solar (CSIQ) 100MW Module Supply Agreement

    http://static.cdn-seekingalpha.com/uploads/2013/12/12/saupload_penny_omega_logo.jpg

    chartstockalert

    http://static.cdn-seekingalpha.com/uploads/2013/12/12/saupload_vvus.jpg

    VIVUS, Inc. (NASDAQ:VVUS) reported that it has entered into a License and Commercialization Agreement with Sanofi to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States including Russia. Sanofi will be responsible for obtaining regulatory approval in its territories.

    Avanafil is licensed from Mitsubishi Tanabe Pharma Corporation. VVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual-dysfunction, with the exception of certain Asian-Pacific Rim countries.

    Erectile-dysfunction (impotence) occurs when a man can no longer get or keep an erection firm enough for sexual-intercourse. Having erection-trouble from time to time isn't necessarily a cause for concern. But if erectile-dysfunction is an ongoing problem, it may cause stress, cause relationship problems or affect your self-confidence.

    Under the terms of the agreement, VVUS is eligible to receive up to $61 million in upfront payments, regulatory and sales milestones. VVUS will also receive escalating royalties based on net sales over the life of the agreement

    Sanofi intends to market avanafil under the tradename SPEDRA(NYSE:TM), the trade name for avanafil in the EU and certain other territories outside of the U.S., which has been approved by the EMA for the treatment of erectile-dysfunction in the EU, or STENDRA(TM), the trade name for avanafil in the U.S. and certain other territories, which is approved by the FDA for the treatment of erectile-dysfunction in the U.S.

    http://static.cdn-seekingalpha.com/uploads/2013/12/12/saupload_vvus_chart1.png

    VVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual-health.

    More about VIVUS, Inc. (VVUS) at www.vivus.com

    **

    http://static.cdn-seekingalpha.com/uploads/2013/10/16/saupload_crwe_logo.jpg

    A social networking service is a platform to build social networks or social relations among people who, for example, share interests, activities, backgrounds, or real-life connections

    Crown Equity Holdings Inc. (OTCPK:CRWE) is currently developing a social networking service and phone app, CRWE Network (CRWE-PR), that is designed to target all the communities in every state of the United States.

    CRWE‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums.

    Looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, CRWE is targeting the multi-billion dollar social networking service market.

    http://static.cdn-seekingalpha.com/uploads/2013/12/12/saupload_crwedec112.png

    CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher.

    More about Crown Equity Holdings Inc. (OTCPK:CRWE) at www.crownequityholdings.com.

    **

    http://static.cdn-seekingalpha.com/uploads/2013/12/12/saupload_csiq1.jpg

    Canadian Solar Inc. (NASDAQ:CSIQ) reported that it has been awarded a module supply agreement to provide Zhenfa New Energy Science & Technology Co., Ltd. with photovoltaic modules totaling 100MW for three solar power projects located in Gansu Province and one solar project in Inner Mongolia Autonomous Region of China.

    CSIQ will supply about 400,000 pieces of its high efficiency CS6P245P, CS6P250P and CS6P-255P modules with power output of 245Wp, 250Wp and 255Wp for the projects. Module deliveries will commence in mid-December 2013 and are expected to be completed in January 2014.

    The three projects in Gansu Province are respectively located in Jiangyuguan, Guliang and Minqin, with a total size of 200MW. The project in Inner Mongolia is located in Sanxin, with a size of 50MW.

    http://static.cdn-seekingalpha.com/uploads/2013/12/12/saupload_csiq_chart.png

    CSIQ is one of the world's largest and foremost solar power companies.

    More about Canadian Solar Inc. (CSIQ) at www.canadiansolar.com.

    **

    Read Full Disclaimer at www.pennyomega.com/disclaimer

    pennyomega.com/28730/stock-alerts/vivus-.../

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Dec 12 9:36 AM | Link | Comment!
  • DELiA Surges Up +12.78% In The Stock Market As Holidays Approach (NASDAQ:DLIA)

    dlia

    dELiA*s, Inc. (NASDAQ:DLIA)

    As the holiday season approaches apon us all, I would like to direct your attention to a hot stock that most would consider in desperate demand with a volume of 4.79 million in play named dELiA*s, Inc. (www.deliasinc.com) ticker DLIA. This Company specializes in multi-channel retail which primarily markets to teenage girls. dELiA*s currently closed Tuesday, Nov. 5, 2013 with a gain of +12.78% Up +0.17 at a price per share rate of a $1.50.

    dliachart

    Now eventhough the Company’s total revenue decreased 16.7% in Q2 of 2013, I must point to the fact that during the same Q2 of fiscal 2013, the Company completed an underwritten follow-on public offering of 15,025,270 shares of its common stock, with proceeds of approximately $14.8 million, net of underwriting discounts and commissions, which were used to repay a portion of the outstanding amounts under its revolving credit facility with Salus Capital. In laymen’s term, they got rid of some debt . As long as this company refocuses their stragey on the brand they might be able to calculate the trend. With holiday sales becoming a reality, I sure Chief Executive Officer Tracy Gardner will know exactly how to focus on this year sales as well as long term growth.

    ****

    crownequityholdings

    Crown Equity Holdings Inc. (OTCMKTS:CRWE)

    Now as long as we are on the topic of sales, I would like to bring attention to Crown Equity Holdings Inc. stock symbol CRWE. Crown Equity Holdings has founded iB2BGlobal which is a B2B trade online directory that has the capability to furnish wholesale and retail needs around the world. While online advertisement revenue around the planet is predicted to be around $24.3 billion this year, iB2BGlobal will enter into a huge market that hopes to bring roughly $262.3 billion.

    crwechart

    With this in mind, some sauve investors would say that this puts Crown Equity Holdings (www.crownequityholdings.com) into a intriguing spot. iB2BGlobal broadens Crown Equity Holdings capacity with other services such as CRWETube (http://CRWETube.com) and global media publishing through thier network of websites. To view iB2BGlobal short form business plan click here http://crownequityholdings.com/extras/iB2BGlobal_business_plan.pdf. Crown Equity Holdings stock symbol CRWE is available at $0.0095 Tuesday, Nov. 5, 2013 and currently represents a +763.63% gain if compared to the 52 week low of $0.0011 .

    (Read Full Disclaimer at http://stock-pr.com/disclaimer). stock-pr.com/23084/stock-alerts/delia-su.../

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Nov 05 7:36 PM | Link | Comment!
Full index of posts »
Latest Followers
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.